Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of novel therapeutics for cancer and viral diseases. It develops a portfolio of clinical and preclinical stage monoclonal antibody-based targeted therapeutics, including bavituximab that is in a multi center Phase I clinical trial for the treatment of solid cancers, as well as a multi center phase Ib clinical trial for the treatment of chronic HCV infection under its anti-phosphatidylserine immunotherapeutic technology platform. The company also develops Cotara, which is a monoclonal antibody targeting agent conjugated to Iodine 131, a therapeutic radioisotope that...